Search Results for “parkinsons” – Page 2 – media

Coya stretches lead drug’s development to Parkinson’s and dementia

Coya Therapeutics is expanding its development plans to study the company’s lead combination therapy COYA-302 in frontotemporal dementia and Parkinson’s disease in addition to amyotrophic lateral sclerosis (ALS) This follows the announcement of successful pre-IND and Type C meetings between Coya and the US Food and Drug Administration (FDA) earlier this month about the candidate. The company plans to file an IND for developing the drug in frontotemporal dementia in Q2 2024 and start a Phase II study the same quarter. The plans for studying COYA-302 in Parkinson’s will follow later, with an IND filing and a Phase I/II start proposed in 2025. In a deal worth up to $677.25m, Dr Reddy’s Laboratories had signed a licence agreement with Coya in December to develop and commercialise COYA 302 to treat ALS in the European Union (EU), the UK, the US and Canada. Under the terms of the agreement, Coya can ...
- Source: drugdu
- 120
- January 19, 2024
Stem-cell-derived brain cells hold promise for Alzheimer’s, Parkinson’s research

Researchers at the University of Wisconsin–Madison have identified a protein key to the development of a type of brain cell believed to play a role in disorders like Alzheimer’s and Parkinson’s diseases and used the discovery to grow the neurons from stem cells for the first time. The stem-cell-derived norepinephrine neurons of the type found in a part of the human brain called the locus coeruleus may enable research into many psychiatric and neurodegenerative diseases and provide a tool for developing new ways to treat them. Yunlong Tao, an investigator at Nanjing University in China who was a research professor at UW–Madison’s Waisman Center when the study was performed, and Su-Chun Zhang, a UW–Madison professor of neuroscience and neurology, published their work on the cells, which they call LC-NE neurons, today in the journal Nature Biotechnology. Norepinephrine neurons in the locus coeruleus regulate heartbeat, blood pressure, arousal, memory, attention and ...
- Source: drugdu
- 114
- November 21, 2023
Spinal stimulation implant offers new hope for Parkinson’s disease treatment

Researchers from the French National Institute of Health and Medical Research, the French National Center for Scientific Research and the University of Bordeaux in France, along with Swiss researchers and neurosurgeons, have successfully designed and tested a spinal stimulation implant to treat Parkinson’s disease. Conducted in collaboration with the Swiss Federal Institute of Technology in Lausanne and the Lausanne university and hospital (UNIL CHUV), the implant was tested to correct disabling gait disorders, which are associated with 90% of people living with advanced Parkinson’s and are often resistant to treatment. Parkinson’s disease is a neurodegenerative condition which progressively damages and leads to a loss of nerve cells in parts of the brain. Gait disorders are commonly caused by weakness of the hip and lower extremity muscles, such as cerebral palsy, muscular dystrophy and spinal muscular dystrophy. The implant directly stimulates nerve cells in the spinal cord responsible for controlling leg ...
- Source: drugdu
- 96
- November 13, 2023
Parkinson’s UK calls on government to mark World Patient Safety Day

The report outlines ways the government can help patients with Parkinson’s disease Parkinson’s UK has called on the government to take action to help people with Parkinson’s disease (PD) get their medication on time in hospital, as part of its relaunched ‘Get It On Time’ campaign to mark World Patient Safety Day on 17 September. The charity, alongside Diabetes UK, Epilepsy Action, National Aids, Rethink Mental Illness and the Richmond Group, supported by the Royal College of Emergency Medicine and the Royal Pharmaceutical Society, outlined in a joint statement how the government can take action to help patients with PD. PD is a progressive neurological condition which affects an estimated 128,000 people in England. People living with PD can experience severe harm to their health, such as trauma, as a result of not receiving their medication on time while in hospital. The issue also affects patients living with diabetes, epilepsy ...
- Source: drugdu
- 131
- October 1, 2023
International survey reveals varying effects of oral medicines for Parkinson’s

An international survey conducted by Parkinson’s Europe, developed in partnership with STADA, has revealed that people taking oral medications for Parkinson’s disease experience varying effects. The survey, financially supported by STADA’s affiliate Brittania Pharmaceuticals, involved 992 participants with advanced Parkinson’s across 53 countries. It revealed that more than 96% of respondents said that they took medication for their condition, two-thirds of which were receiving oral levodopa or another single oral therapy. Parkinson’s disease is a neurodegenerative disease that progressively damages parts of the brain. Symptoms of advanced Parkinson’s are more complex and have a stronger effect on day-to-day life. The study revealed that 65% of respondents reported varying effects; 42% reported a partial response without the usual resolution of motor symptoms; 40% reported a delayed onset of effect; and 60% reported that they ‘regularly’ or ‘often’ experienced the effect of a medication wearing off before the next dose. It also ...
- Source: drugdu
- 101
- September 4, 2023
Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Bayer and BlueRock Therapeutics have announced positive results from their phase 1 stem cell clinical trial, showing that the treatment improved symptoms of Parkinson’s disease. The trial results were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Parkinson’s disease is the fastest-growing neurodegenerative disease in the world and causes parts of the brain to become progressively damaged over many years. The condition affects around 145,000 people in the UK. As part of the trial, a total of 12 people with Parkinson’s underwent surgery to receive either a high or low dose of bemdaneprocel (BRT-DA01), an experimental therapy involving dopamine-producing cells developed from stem cells. Stem cells develop different types of specialised cells, including skin, muscle or brain cells. For years, researchers have been working to find a way to convert stem cells into dopamine-producing brain cells to be used to replace those that are ...
- Source: drugdu
- 101
- September 1, 2023
Study reveals gut conditions could be early sign of Parkinson’s disease

New research published in the journal Gut suggests that certain gastrointestinal symptoms could be an early warning sign of Parkinson’s disease. Symptoms including constipation, dysphagia (difficulty swallowing) and irritable bowel syndrome (IBS) are suspected to drive the development of Parkinson’s disease, along with cerebrovascular disease (CD), such as a stroke or brain aneurysm, and Alzheimer’s disease (AD). Parkinson’s is one of the fastest-growing neurodegenerative diseases in the world and affects around 145,000 people in the UK. There is currently no cure for the condition. Researchers analysed the US medical records of 24,624 people with Parkinson’s and compared them to 19,046 people with AD, 23,942 with CD, and 24,624 with healthy brains to determine whether patients with Parkinson’s experienced gut issues six years prior to diagnosis and whether they had a higher chance of developing the condition. The gastrointestinal tract possesses millions of nerve cells that communicate with the brain. Researchers ...
- Source: drugdu
- 119
- August 31, 2023
Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

Bayer AG and its subsidiary, BlueRock Therapeutics LP, have announced positive topline results from an early-stage study of an experimental Parkinson’s disease stem cell therapy. In the phase 1 study of bemdaneprocel, the treatment was shown to be well-tolerated in all 12 patients involved in the study, and transplanted cells grew as intended in the patients’ brains at one-year post-transplant. The companies said that, based on these positive results, planning is already underway for a phase 2 study that is expected to begin enrolling patients in the first half of 2024. There is no cure for Parkinson’s disease, a progressive and chronic neurological disorder that affects an estimated ten million people worldwide. The disease is caused by nerve cell damage in the brain, which leads to decreased levels of dopamine. The loss of these dopaminergic neurons results in a progressive decline of motor function and symptoms such as tremors, muscle ...
- Source: drugdu
- 110
- July 1, 2023
Is Parkinson’s disease, ‘world’s fastest growing brain disease,’ mostly preventable?

Researchers warn that a colorless chemical known as trichloroethylene (TCE) — which has been used to dry-clean clothes, degrease metals and decaffeinate coffee — may be linked to the dramatic increase in Parkinson’s disease (PD) cases. They recently published a series of seven cases in the Journal of Parkinson’s disease that illustrate TCE’s harmful health effects and the potential PD association. “TCE is associated with a 500% increased risk of Parkinson’s disease,” lead author Dr. Ray Dorsey, professor of neurology at the University of Rochester in New York and author of “Ending Parkinson’s Disease,” told Fox News Digital. The chemical reproduces the features of the neurological disease in laboratory animals. It impairs the function of the energy-producing parts of cells called mitochondria, which are known to be damaged in Parkinson’s disease, Dorsey added. Widespread applications of TCE TCE was first synthesized in the lab in ...
- Source: drugdu
- 151
- March 30, 2023
FDA Approves New Drug to Treat Parkinson’s Disease, Providing Hope for Millions of Patients

The US Food and Drug Administration (FDA) has approved a new drug to treat Parkinson’s disease, providing hope for millions of patients who suffer from this debilitating condition. The drug, called Levodopa/Carbidopa Enteral Suspension (LCES), is the first new treatment for Parkinson’s disease to be approved by the FDA in over a decade. Parkinson’s disease is a progressive neurodegenerative disorder that affects movement and is caused by the degeneration of dopamine-producing neurons in the brain. The symptoms of Parkinson’s disease include tremors, stiffness, and difficulty with coordination and movement. LCES is a combination of two drugs, Levodopa and Carbidopa, that work together to increase the levels of dopamine in the brain. This can help to improve the symptoms of Parkinson’s disease and provide relief for patients. The approval of LCES is a significant development in the treatment of Parkinson’s disease, which has been largely treated with the ...
- Source: drugdu
- 125
- March 24, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.